-DOCSTART- -X- O
Since -X- _ O
1997 -X- _ O
, -X- _ O
several -X- _ O
epizootic -X- _ B-Patient
avian -X- _ I-Patient
influenza -X- _ I-Patient
viruses -X- _ I-Patient
( -X- _ I-Patient
AIVs -X- _ I-Patient
) -X- _ I-Patient
have -X- _ O
been -X- _ O
transmitted -X- _ O
to -X- _ O
humans -X- _ O
, -X- _ O
causing -X- _ O
diseases -X- _ O
and -X- _ O
even -X- _ O
deaths. -X- _ O
The -X- _ O
recent -X- _ O
emergence -X- _ O
of -X- _ O
severe -X- _ O
human -X- _ O
infections -X- _ O
with -X- _ O
AIV -X- _ O
( -X- _ O
H7N9 -X- _ B-Patient
) -X- _ O
in -X- _ O
China -X- _ O
has -X- _ O
raised -X- _ O
concerns -X- _ O
about -X- _ O
efficient -X- _ O
interpersonal -X- _ O
viral -X- _ O
transmission -X- _ O
, -X- _ O
polygenic -X- _ O
traits -X- _ O
in -X- _ O
viral -X- _ O
pathogenicity -X- _ O
and -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
newly -X- _ O
emerging -X- _ O
strains. -X- _ O
The -X- _ O
symptoms -X- _ O
associated -X- _ O
with -X- _ O
viral -X- _ O
infection -X- _ O
are -X- _ O
different -X- _ O
in -X- _ O
various -X- _ O
AI -X- _ O
strains -X- _ O
: -X- _ O
H5N1 -X- _ B-Outcome
and -X- _ I-Outcome
newly -X- _ I-Outcome
emerged -X- _ I-Outcome
H7N9 -X- _ I-Outcome
induce -X- _ I-Outcome
severe -X- _ I-Outcome
pneumonia -X- _ I-Outcome
and -X- _ I-Outcome
related -X- _ I-Outcome
complications -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
some -X- _ I-Outcome
H7 -X- _ I-Outcome
and -X- _ I-Outcome
H9 -X- _ I-Outcome
subtypes -X- _ I-Outcome
cause -X- _ I-Outcome
only -X- _ I-Outcome
conjunctivitis -X- _ I-Outcome
or -X- _ I-Outcome
mild -X- _ I-Outcome
respiratory -X- _ I-Outcome
symptoms. -X- _ I-Outcome
The -X- _ O
virulence -X- _ O
and -X- _ O
tissue -X- _ O
tropism -X- _ O
of -X- _ O
viruses -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
the -X- _ O
host -X- _ O
responses -X- _ O
contribute -X- _ O
to -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
human -X- _ B-Patient
AIV -X- _ I-Patient
infection. -X- _ I-Patient
Several -X- _ O
preventive -X- _ O
and -X- _ O
therapeutic -X- _ O
approaches -X- _ O
have -X- _ O
been -X- _ O
proposed -X- _ O
to -X- _ O
combat -X- _ O
AIV -X- _ O
infection -X- _ O
, -X- _ O
including -X- _ O
antiviral -X- _ B-Intervention
drugs -X- _ I-Intervention
such -X- _ I-Intervention
as -X- _ I-Intervention
M2 -X- _ I-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
neuraminidase -X- _ I-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
RNA -X- _ I-Intervention
polymerase -X- _ I-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
attachment -X- _ I-Intervention
inhibitors -X- _ I-Intervention
and -X- _ I-Intervention
signal-transduction -X- _ I-Intervention
inhibitors -X- _ I-Intervention
etc. -X- _ O
In -X- _ O
this -X- _ O
article -X- _ O
, -X- _ O
we -X- _ O
summarize -X- _ O
the -X- _ O
recent -X- _ O
progress -X- _ O
in -X- _ O
researches -X- _ O
on -X- _ O
the -X- _ O
epidemiology -X- _ O
, -X- _ O
clinical -X- _ O
features -X- _ O
, -X- _ O
pathogenicity -X- _ O
determinants -X- _ O
, -X- _ O
and -X- _ O
available -X- _ O
or -X- _ O
potential -X- _ O
antivirals -X- _ O
of -X- _ O
AIV -X- _ O
. -X- _ O

